Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.030
+0.010 (0.98%)
Jul 11, 2025, 4:00 PM - Market closed
Lineage Cell Therapeutics Employees
As of December 31, 2024, Lineage Cell Therapeutics had 77 total employees, including 70 full-time and 7 part-time employees. The number of employees increased by 2 or 2.67% compared to the previous year.
Employees
77
Change (1Y)
2
Growth (1Y)
2.67%
Revenue / Employee
$124,117
Profits / Employee
-$210,468
Market Cap
235.21M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LCTX News
- 20 days ago - Two Biotech Stocks Poised For Big Moves On Monday - Benzinga
- 20 days ago - OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025 - Business Wire
- 5 weeks ago - Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - Business Wire
- 2 months ago - Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire
- 2 months ago - Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 - Business Wire
- 2 months ago - Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - Business Wire